title: Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density.
abstract: OBJECTIVE
  To assess the efficacy, safety, and effect on bone mineral density of a 3-month course of retreatment with intranasal nafarelin acetate for recurrent symptoms of endometriosis.
  
  
  METHODS
  Multicenter, open-label, nonrandomized clinical trial.
  
  
  METHODS
  Eleven hospital-based and private practices.
  
  
  METHODS
  Thirty-six women with endometriosis symptoms recurring after 3 or 6 months of treatment with nafarelin.
  
  
  METHODS
  Nasal nafarelin 200 micrograms twice daily for 3 months.
  
  
  METHODS
  Assessments for dysmenorrhea, dyspareunia, pelvic pain, tenderness, and induration. Measurement of bone mineral density of the lumbar spine.
  
  
  RESULTS
  Improvements from admission to the end of retreatment were significant for dysmenorrhea, pelvic pain, tenderness, induration, and dyspareunia. Three months after retreatment ended, mean symptom scores for dysmenorrhea and pelvic tenderness, although worse than at the end of retreatment, were still significantly better than scores at admission. Mean bone mineral density 3 months after retreatment was 0.56% lower than before retreatment and 1.94% lower than before initial treatment.
  
  
  CONCLUSIONS
  Three-month nafarelin retreatment for recurrent endometriosis symptoms was effective and safe.
authors.affiliation: Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Hornstein
authors.forename: A A
authors.initials: AA
authors.lastname: Yuzpe
authors.forename: K
authors.initials: K
authors.lastname: Burry
authors.forename: V C
authors.initials: VC
authors.lastname: Buttram
authors.forename: L R
authors.initials: LR
authors.lastname: Heinrichs
authors.forename: R M
authors.initials: RM
authors.lastname: Soderstrom
authors.forename: E
authors.initials: E
authors.lastname: Steinberger
authors.forename: J S
authors.initials: JS
authors.lastname: Lin
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D004412:Dysmenorrhea / Q000139:chemically induced; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006728:Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D017274:Nafarelin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010146:Pain; D012008:Recurrence
chemical_list: D006728:Hormones; D017274:Nafarelin